Recent Finacing
Recent Raise
Commit Biologics develops the BiCE™ platform using single‑domain antibodies to engage C1q and arm conventional antibodies to direct complement-mediated cytotoxicity against tumor and autoimmune targets.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Commit Biologics.
